



Myositis-associated ILD: update on treatment approaches and challenges

Robert Hallowell, MD

Disclosures

- Speaking and consulting fees from Boehringer Ingelheim, Genentech, Vicore
- Research trials with Boehringer, Genentech, Galapagos, Hoffmann-La Roche, Nitto Denko
- Authorship fees from UpToDate, Dynamed





ILD is common in patients with myositis

• Reported prevalence in DM/PM is 20% -78%

• Reported prevalence with anti-synthetase antibodies is 71-100%

• ILD precedes the diagnosis of myositis in 13% to 37.5% of patients




Marie et al. Arthritis Rheum 2011;63:3439-47. Chen et al. Clin Rheumatol 2009;28:639-46 Yu et al. Clin Rheumatol 2011;30:1595-601 Hamaguchi et al. PLoS ONE 2013;8(4):e60442



2023 American College of Rheumatology (ACR) Guideline


for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Disease (SARD)





2023 American College of Rheumatology (ACR) Guideline


for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Disease (SARD)






Myositis-ILD can be stabilized by a variety of agents

46 patients with PM/DM-ILD (50% had Jo-1) Cyclophosphamide 24 Azathioprine 13 Mycophenolate 9






FVC increased by 5%

Ave prednisone dose: 40 mg/d pre-treatment; 10-16 mg/d at 6 months; 7.5 mg/d at 12 months



Azathioprine vs Mycophenolate in myositis-ILD



Ave prednisone dose at initiation: 28 (AZA) vs 18 (MMF) AZA group had more adverse events: LFTs, cytopenias, GI symptoms (33% vs 13%)



Huapaya et al. CHEST 2019; 156(5):896-906

Tacrolimus for refractory myositis-ILD

54 patients with myositis-ILD received prednisone plus AZA, MTX, or MMF ~ 50% had an anti-synthetase Ab

Response to conventional Tx (57%) PM-ILD 67% DM-ILD 35% p = 0.013

23 patients (43%) failed to respond to conventional therapy

→ Received add-on therapy with either CYC (5) or tacrolimus (18)

Response to tacrolimus

ILD improved in 94%


Decrease in prednisone At 3-6 months 65% At 12 months 81%



Timing of calcineurin inhibitors may matter for myositis-ILD

47 DM-ILD patients who ultimately received CsA (all received steroids) Early Tx = within two weeks Delayed Tx = Ave 5.3 mo after ILD dx

- Often received other steroid-sparing agents first





*Rate of CADM higher in early group 62.5% vs 29% (p = 0.34)



Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial

- All had an NSIP pattern of disease (CTD, IPAF, or idiopathic)
- MMF 2g daily + Rituximab/Placebo for 6 months
- 63 received RTX; 59 received placebo








RTX vs CYC for antisynthetase associated-ILD

CYC 34 patients (88% received subsequent steroid-sparing agents) RTX 28 patients (54% received subsequent steroid-sparing agents)




*CYC has statistically significant lower FVC and DLCO at baseline



IVIg for treating myositis-ILD


Retrospective review of patients with MDA5+ RP-ILD

- 17 patients received standard therapy (CYC, CNI, RTX, Tofac)
- 31 patients received IVIG + standard therapy






Tofacitinib for MDA5-ILD




- -- ILD for less than 3 months
- -- Well matched for disease severity



26 patients received TOF; 35 received TAC

- --Groups were relatively well matched
- --More Ro52 in TOF group

--More high-titer MDA-5 in TAC group




days from first HRCT presentation of ILD to death

Mortality rates TOF vs TAC groups 6-month (38.5% vs 62.9%; P = 0.03) 1-year (44.0% vs 65.7%; P = 0.03)



Myositis patients can develop a progressive fibrotic phenotype





INBUILD — Nintedanib is effective for patients with PF-ILD (non-IPF)






Table 2. Efficacy End Points.*			
End Point	Nintedanib (N=332)	Placebo (N = 331)	Difference (95% CI)
Primary end point			
Rate of decline in the FVC at 52 wk — ml/yr†			
Overall population	-80.8±15.1	-187.8±14.8	107.0 (65.4 to 148.5)‡
Patients with a UIP-like fibrotic pattern	-82.9±20.8	-211.1±20.5	128.2 (70.8 to 185.6)‡
Patients with other fibrotic patterns	-79.0±21.6	-154.2±21.2	75.3 (15.5 to 135.0)§




The INBUILD trial included RA but not myositis patients





--Difference in FVC decline vs placebo 104 mL/year





Plasma Exchange for RP-ILD





Fig. 2. Kaplan-Meier Curves for the One-Year Transplant-Free Survival According to the use of Plasma Exchange.



Treatment algorithm





RW Hallowell and SK Danoff. Chest 2023, online, in press

Summary

Standard therapy for the treatment of myositis-ILD involves the use of steroid-sparing agents

There is no strong data to suggest that one agent is superior to another!

Although antifibrotics are routinely used in patients with a progressively fibrotic component, this practice is not based on strong clinical data

Clinical trials are needed to guide our understanding of how best to care for this complex patient population

